Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

PPAR Research

Volumn 2016, Issue , 2016, Pages

  Oidor Chan, Víctor Hugo ^a,b   Hong, Enrique ^a   Pérez Severiano, Francisca ^c   Montes, Sergio ^c   Torres Narvaéz, Juan Carlos ^b   Del Valle Mondragón, Leonardo ^b   Pastelín Hernández, Gustavo ^b   Sánchez Mendoza, Alicia ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROBIOPTERIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDUCIBLE NITRIC OXIDE SYNTHASE; METFORMIN; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; HEART INFARCTION SIZE; HEART PROTECTION; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

EID: 84962667021     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2016/8237264     Document Type: Article

References (46)

1. R. A. DeFronzo, "Pharmacologic therapy for type 2 diabetes mellitus, " Annals of Internal Medicine, vol. 131, no. 4, pp. 281-303, 1999.
2. S. P. Gray and K. Jandeleit-Dahm, "The pathobiology of diabetic vascular complications-cardiovascular and kidney disease, " Journal of Molecular Medicine, vol. 92, no. 5, pp. 441-452, 2014.
3. P.-Y. Zhang, "Cardiovascular disease in diabetes, " European Review forMedical and Pharmacological Sciences, vol. 18, no. 15, pp. 2205-2214, 2014.
4. M. Aragno, R. Mastrocola, C. Medana et al., "Oxidative stressdependent impairment of cardiac-specific transcription factors in experimental diabetes, " Endocrinology, vol. 147, no. 12, pp. 5967-5974, 2006.
5. R. B. Wichi, V. Farah, Y. Chen, M. C. Irigoyen, M. Morris, "Deficiency in angiotensin AT1a receptors prevents diabetesinduced hypertension, " The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 292, no. 3, pp. R1184-R1189, 2007.
6. H. Li and U. Förstermann, "Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease, " Current Opinion in Pharmacology, vol. 13, no. 2, pp. 161-167, 2013.
7. A. A. Bulhak, C. Jung, C.-G. Ostenson, J. O. Lundberg, P.-O. Sjöquist, J. Pernow, "PPAR-activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt andNOpathway, "TheAmerican Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 3, pp. H719-H727, 2009.
8. C. Dumitrescu, R. Biondi, Y. Xia et al., "Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BHIN4, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15081-15086, 2007.
9. U. Förstermann and W. C. Sessa, "Nitric oxide synthases: regulation and function, " European Heart Journal, vol. 33, no. 7, pp. 829-837, 2012.
10. A. Magenta, S. Greco, M. C. Capogrossi, C. Gaetano, F. Martelli, "Nitric oxide, oxidative stress, p66Shc interplay in diabetic endothelial dysfunction, " BioMed Research International, vol. 2014, Article ID 193095, 16 pages, 2014.
11. R. Eldor, R. A. DeFronzo, M. Abdul-Ghani, "In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, insulin secretion, " Diabetes Care, vol. 36, supplement 2, pp. S162-S174, 2013.
12. P. R. Holden and J. D. Tugwood, "Peroxisome proliferatoractivated receptor alpha: role in rodent liver cancer and species differences, " Journal of Molecular Endocrinology, vol. 22, no. 1, pp. 1-8, 1999.
13. L. G. Cervantes-Pérez, M. D. Ibarra-Lara, B. Escalante et al., "Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension, " European Journal of Pharmacology, vol. 685, no. 1-3, pp. 108-115, 2012.
14. T.-L. Yue, W. Bao, B. M. Jucker et al., "Activation of peroxisome proliferator-activated receptor-protects the heart from ischemia/reperfusion injury, " Circulation, vol. 108, no. 19, pp. 2393-2399, 2003.
15. N. S. Wayman, Y. Hattori, M. C. McDonald et al., "Ligands of the peroxisome proliferator-activated receptors (PPAR-and PPAR-) reduce myocardial infarct size, " The FASEB Journal, vol. 16, no. 9, pp. 1027-1040, 2002.
16. G. Barreto-Torres, R. Parodi-Rullán, S. Javadov, "The role of PPAR in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats, " International Journal of Molecular Sciences, vol. 13, no. 12, pp. 7694-7709, 2012.
17. L. Ibarra-Lara, E. Hong, E. Soria-Castro et al., "Clofibrate PPAR activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flowmyocardial ischemia, " Journal of Cardiovascular Pharmacology, vol. 60, no. 4, pp. 323-334, 2012.
18. L. Flohé and F. Otting, "Superoxide dismutase assays, " Methods in Enzymology, vol. 105, pp. 93-104, 1984.
19. F. A. Tenorio and L. P. G. del Valle, "Validación de un método anaĺtico espectrofotométrico para la cuantificación de metabolitos estables de óxido ńtrico en fluidos biológicos Validation of a spectrophotometric analyticalmethod for quantifying stable, " RevistaMexicana de Ciencias Farmaceúticas, vol. 36, no. 1, pp. 31-41, 2005.
20. Y. Hu, Y. Chen, L. Ding et al., "Pathogenic role of diabetesinduced PPAR-down-regulation in microvascular dysfunction, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 38, pp. 15401-15406, 2013.
21. S. Narravula and S. P. Colgan, "Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor expression during hypoxia, " Journal of Immunology, vol. 166, no. 12, pp. 7543-7548, 2001.
22. V. Chavali, S. C. Tyagi, P. K. Mishra, "Predictors and prevention of diabetic cardiomyopathy, " Diabetes, Metabolic Syndrome and Obesity: Targets andTherapy, vol. 6, pp. 151-160, 2013.
23. S. W. Schaffer, B. H. Tan, G. L. Wilson, "Development of a cardiomyopathy in amodel of noninsulin-dependent diabetes, " The American Journal of Physiology, vol. 248, no. 2, pp. H179-H185, 1985.
24. D. Aronson, A. Musallam, J. Lessick et al., "Impact of diastolic dysfunction on the development of heart failure in diabetic patients after acute myocardial infarction, " Circulation: Heart Failure, vol. 3, no. 1, pp. 125-131, 2010.
25. M. Guerre-Millo, P. Gervois, E. Raspé et al., "Peroxisome proliferator-activated receptor activators improve insulin sensitivity and reduce adiposity, " The Journal of Biological Chemistry, vol. 275, no. 22, pp. 16638-16642, 2000.
26. J. Rieusset, M. Roques, K. Bouzakri, E. Chevillotte, H. Vidal, "Regulation of p85 phosphatidylinositol-3-kinase expression by peroxisome proliferator-activated receptors (PPARs) in human muscle cells, " FEBS Letters, vol. 502, no. 3, pp. 98-102, 2001.
27. I. Pavo, G. Jermendy, T. T. Varkonyi et al., "Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes, " Journal of Clinical Endocrinology andMetabolism, vol. 88, no. 4, pp. 1637-1645, 2003.
28. T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, I. Yamaguchi, "Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factorkappa-B pathway, " Journal of the American College of Cardiology, vol. 43, no. 8, pp. 1481-1488, 2004.
29. S. Ichihara, K. Obata, Y. Yamada et al., "Attenuation of cardiac dysfunction by a PPAR-agonist is associated with downregulation of redox-regulated transcription factors, " Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 318-329, 2006.
30. T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, I. Yamaguchi, "Stimulation of peroxisome-proliferatoractivated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts, " Clinical Science, vol. 103, supplement, pp. 284S-288S, 2002.
31. M. Rose, P. Balakumar, M. Singh, "Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats, " Pharmacology, vol. 80, no. 2-3, pp. 177-184, 2007.
32. T. Li, Q. Zhang, J. Zhang et al., "Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-B pathway, " BMC Cancer, vol. 14, article 96, 2014.
33. G. S. Bhamra, D. J. Hausenloy, S. M. Davidson et al., "Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening, " Basic Research in Cardiology, vol. 103, no. 3, pp. 274-284, 2008.
34. J. W. Calvert, S. Gundewar, S. Jha et al., "Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling, " Diabetes, vol. 57, no. 3, pp. 696-705, 2008.
35. M. Paiva, N. P. Riksen, S. M. Davidson et al., "Metformin preventsmyocardial reperfusion injury by activating the adenosine receptor, " Journal of Cardiovascular Pharmacology, vol. 53, no. 5, pp. 373-378, 2009.
36. A. A. Bulhak, P.-O. Sjöquist, C.-B. Xu, L. Edvinsson, J. Pernow, "Protection against myocardial ischaemia/reperfusion injury by PPAR-activation is related to production of nitric oxide and endothelin-1, " Basic Research in Cardiology, vol. 101, no. 3, pp. 244-252, 2006.
37. S. P. Jones, J. J. M. Greer, A. K. Kakkar et al., "Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 286, no. 1, pp. H276-H282, 2004.
38. A. Rubio-Guerra, "Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients" Integrated Blood Pressure Control, vol. 2010, no. 3, pp. 125-132, 2010.
39. N. J. Alp, M. A. McAteer, J. Khoo, R. P. Choudhury, K. M. Channon, "Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atheroscleroses in ApoEknockout mice, " Arteriosclerosis, Thrombosis, Vascular Biology, vol. 24, no. 3, pp. 445-450, 2004.
40. S. Cai, N. J. Alp, D. McDonald et al., "GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation, " Cardiovascular Research, vol. 55, no. 4, pp. 838-849, 2002.
41. S. Wang, J. Xu, P. Song, B. Viollet, M.-H. Zou, "In vivo activation of AMP-activated protein kinase attenuates diabetesenhanced degradation of GTP cyclohydrolase I, " Diabetes, vol. 58, no. 8, pp. 1893-1901, 2009.
42. Z.-D. Ge, I. A. Ionova, N. Vladic et al., "Cardiac-specific overexpression of GTP cyclohydrolase 1 restores ischaemic preconditioning during hyperglycaemia, " Cardiovascular Research, vol. 91, no. 2, pp. 340-349, 2011.
43. J. Liu, C. Lu, F. Li et al., "PPAR-agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of Guanosine 5-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells, " PPAR Research, vol. 2011, Article ID 523520, 8 pages, 2011.
44. M. Nieuwdorp, E. S. G. Stroes, J. J. P. Kastelein, "Normalization of metabolic syndrome using fenofibrate, metformin or their combination, "Diabetes, Obesity andMetabolism, vol. 9, no. 6, pp. 869-878, 2007.
45. R. Krysiak, A. Gdula-Dymek, B. Okopien, "Lymphocytesuppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance, " Pharmacological Reports, vol. 65, no. 2, pp. 429-434, 2013.
46. R. Krysiak, A. Gdula-Dymek, B. Okopién, "Effect of metformin on selected parameters of hemostasis in fenofibratetreated patients with impaired glucose tolerance, " Pharmacological Reports, vol. 65, no. 1, pp. 208-213, 2013.